Literature DB >> 7978724

Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum.

S E Vartivarian1, K A Papadakis, J A Palacios, J T Manning, E J Anaissie.   

Abstract

OBJECTIVE: To describe the mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia in patients with cancer.
DESIGN: A retrospective 15-month clinical study.
SETTING: Academic, referral-based cancer center. PATIENTS: Of 237 patients with X. maltophilia isolated from all sites during the 15-month study period, 114 patients were judged to have true X. maltophilia infections. Only patients with mucocutaneous and soft tissue infections were included in the study.
RESULTS: 17 (15%) of the 114 patients with X. maltophilia infection had mucocutaneous and soft tissue infections: Six patients had metastatic cellulitis, 5 had primary cellulitis usually associated with catheter use, and 6 had infected mucocutaneous ulcers. The metastatic cellulitis consisted of previously undescribed multiple, hard, tender nodules with surrounding and distant cellulitis (5 patients) or ecthyma gangrenosum (1 patient). Four of these patients died of the infection. Metastatic cellulitis and mucocutaneous infections occurred in hospitalized, neutropenic patients who received broad-spectrum antibiotics (beta-lactams, quinolones), often with in vitro activity against the infecting organisms. Response usually correlated with recovery from myelosuppression and administration of trimethoprim-sulfamethoxazole with or without ticarcillin-clavulanate. Catheter removal contributed to response in the treatment of primary cellulitis.
CONCLUSIONS: Mucocutaneous and soft tissue infections caused by X. maltophilia are not uncommon, and X. maltophilia can cause metastatic nodular skin lesions that mimic disseminated fungal infections. It also causes serious morbidity and high mortality in patients with metastatic skin nodules and can cause superinfections in patients receiving broad-spectrum beta-lactam or quinolone antibiotics to which the organisms are susceptible when the infections develop. Catheter removal contributes to a favorable outcome in patients with catheter-associated cellulitis without bacteremia. Xanthomonas maltophilia infection should be added to the differential diagnosis of mucocutaneous or soft tissue infection in patients with cancer. Trimethoprim-sulfamethoxazole with or without ticarcillin-clavulanate is the current treatment of choice for culture-proven infections, but early empiric therapy may improve outcome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7978724     DOI: 10.7326/0003-4819-121-12-199412150-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  22 in total

1.  Pseudo-, Xantho-, and now Stenotrophomonas maltophilia: New kid on the block.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1996-03

2.  Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system.

Authors:  L Zhang; X Z Li; K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Non healing leg ulcer infected with Stenotrophomonas maltophilia: first reported case from India.

Authors:  Falguni Nag; Abhishek De; Kokila Banerjee; Gobinda Chatterjee
Journal:  Int Wound J       Date:  2012-01-31       Impact factor: 3.315

4.  Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.

Authors:  G Aisenberg; K V Rolston; B F Dickey; D P Kontoyiannis; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

5.  Stenotrophomonas (Xanthomonas) maltophilia infection in necrotizing pancreatitis.

Authors:  K E Mönkemüller; D E Morgan; T H Baron
Journal:  Int J Pancreatol       Date:  1999-02

6.  Disseminated invasive infection due to Metarrhizium anisopliae in an immunocompromised child.

Authors:  D Burgner; G Eagles; M Burgess; P Procopis; M Rogers; D Muir; R Pritchard; A Hocking; M Priest
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

Review 7.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 8.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 9.  Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  R G Munter; A M Yinnon; Y Schlesinger; C Hershko
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

Review 10.  Community-acquired Stenotrophomonas maltophilia infections: a systematic review.

Authors:  M E Falagas; A C Kastoris; E K Vouloumanou; G Dimopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-18       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.